ATE130765T1 - Gentechnologisch veränderte immunglobuline. - Google Patents

Gentechnologisch veränderte immunglobuline.

Info

Publication number
ATE130765T1
ATE130765T1 AT90904172T AT90904172T ATE130765T1 AT E130765 T1 ATE130765 T1 AT E130765T1 AT 90904172 T AT90904172 T AT 90904172T AT 90904172 T AT90904172 T AT 90904172T AT E130765 T1 ATE130765 T1 AT E130765T1
Authority
AT
Austria
Prior art keywords
genetically modified
modified immunoglobulins
preparing
found
immunoglobulins
Prior art date
Application number
AT90904172T
Other languages
English (en)
Inventor
Maurizio Zanetti
Maurizio Sollazzo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23227670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE130765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE130765T1 publication Critical patent/ATE130765T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90904172T 1989-02-24 1990-02-23 Gentechnologisch veränderte immunglobuline. ATE130765T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31614489A 1989-02-24 1989-02-24

Publications (1)

Publication Number Publication Date
ATE130765T1 true ATE130765T1 (de) 1995-12-15

Family

ID=23227670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90904172T ATE130765T1 (de) 1989-02-24 1990-02-23 Gentechnologisch veränderte immunglobuline.

Country Status (9)

Country Link
US (3) US5508386A (de)
EP (1) EP0460076B1 (de)
JP (2) JP3355351B2 (de)
AT (1) ATE130765T1 (de)
CA (1) CA2047244C (de)
DE (2) DE69023900D1 (de)
DK (1) DK0460076T3 (de)
ES (1) ES2082850T3 (de)
WO (1) WO1990009804A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0460076T3 (da) * 1989-02-24 1996-03-25 Univ California Genetisk manipulerede immunoglobuliner
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
SI0910407T1 (en) * 1996-05-15 2003-10-31 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1030684A4 (de) * 1997-11-14 2004-09-15 Euro Celtique Sa Modifizierte antikörper mit verstärkter fähigkeit eine anti-idiotypische antwort auszulösen
WO1999033965A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
AU753753B2 (en) * 1998-11-13 2002-10-24 Euro-Celtique S.A. Contraceptive antibody vaccines
CA2362928A1 (en) * 1999-02-25 2000-08-31 Tai-June Yoo Vaccine for house dust mite allergen using naked plasmid dna
WO2000064488A2 (en) * 1999-04-27 2000-11-02 Eurogen Holding, S.A. Somatic transgene immunization and related methods
EP1246643A4 (de) 1999-10-14 2005-05-11 Jeffery A Ledbetter Dna impfstoffe, welcheein antigen kodieren, dass an eine cd40-bindende domäne bindet
WO2001060391A1 (en) * 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
US6801270B2 (en) * 2000-06-26 2004-10-05 Reveo, Inc. Backlight for a liquid crystal display having high light-recycling efficiency
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
AU2002326751A1 (en) 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
EP2258712A3 (de) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
CA2479187A1 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US7939641B2 (en) * 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
WO2003086041A2 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
EP1496934A4 (de) * 2002-04-19 2006-08-02 Endocyte Inc Adjuvante verbesserte immunotherapie
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP5162250B2 (ja) * 2005-01-13 2013-03-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬を使用するｅｌｉｓａアッセイ
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
EP1887084A1 (de) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1230299A (fr) * 1982-11-30 1987-12-15 Marc Girard Peptides comportant un site immunogene du poliovirus et adns contenant des sequences nucleotidiques codant pour ces peptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
DK0460076T3 (da) * 1989-02-24 1996-03-25 Univ California Genetisk manipulerede immunoglobuliner
EP0580758A4 (de) * 1991-04-18 1995-04-05 Sinai School Medicine Rekombinante antikörper gegen menschlichen immunschwächevirus.

Also Published As

Publication number Publication date
US5508386A (en) 1996-04-16
CA2047244A1 (en) 1990-08-25
DE69023900D1 (de) 1996-01-11
US5583202A (en) 1996-12-10
DE69023900T4 (de) 1996-10-02
CA2047244C (en) 2002-09-17
JP3355351B2 (ja) 2002-12-09
EP0460076B1 (de) 1995-11-29
WO1990009804A1 (en) 1990-09-07
DK0460076T3 (da) 1996-03-25
DE69023900T2 (de) 1996-07-04
JP3357890B2 (ja) 2002-12-16
EP0460076A4 (en) 1992-08-05
ES2082850T3 (es) 1996-04-01
JPH04503605A (ja) 1992-07-02
EP0460076A1 (de) 1991-12-11
JP2001190295A (ja) 2001-07-17
US5658762A (en) 1997-08-19

Similar Documents

Publication Publication Date Title
DE69023900D1 (de) Gentechnologisch veränderte immunglobuline.
SE9201331D0 (sv) Protein l och hybridproteiner daerav
CY1793A (en) Recombinant immunoglobulin preparations methods for their preparation DNA sequences expression vectors and recombinant host cells therefor
DE3750339D1 (de) HTLV-III umhüllende Peptiden.
ATE387458T1 (de) Fas-antigenbindender ligand
PT96097A (pt) Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
ES2098274T3 (es) Anticuerpos monoclonales.
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
FI103730B1 (fi) Molekyylikloonauksella aikaansaadut haiman saarekesoluantigeenit
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
NO174153C (no) Antigen og monoklonalt antistoff for anvendelse in vitro, samt immunologiske reagenser inneholdende disse
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
DE60025522D1 (de) Mycoplasma mycoides subsp. mycoides sc antigenisches lppq protein, seine herstellung und verwendung
FI870501L (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
DE68926813D1 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
MX24651A (es) Compuestos de adn recombinante, vectores de expresion de mutantes de glicosilacion de la proteina c humana, celulas huesped transformadas y metodo para la produccion recombinante de formas zimogenas de proteina c humana.
DE69931282D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
NO912192D0 (no) Rekombinante dna og fremgangsmaate for fremstilling av chimere antistoffer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee